- Home
- DWTX
as 04-02-2025 4:00pm EST
Stocks
Dogwood Therapeutics Inc formerly Virios Therapeutics Inc is a development-stage biotechnology company. It is focused advancing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response, such as fibromyalgia (FM) and Long-COVID (LC). Its product candidates includes IMC-1 and IMC-2, IMC-1, is intended to synergistically suppress herpesvirus activation and replication with a more specific activity against the Epstein-Barr virus (herpesvirus HHV-4, IMC-2 is a combination of valacyclovir and celecoxib.
| Founded: | 2012 | Country: | United States |
| Employees: | N/A | City: | ALPHARETTA |
| Market Cap: | 5.9M | IPO Year: | N/A |
| Target Price: | N/A | AVG Volume (30 days): | 3.1M |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -12.52 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.62 - $29.28 | Next Earning Date: | 03-31-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest DOGWOOD THERAPEUTICS INC News
DWTX Breaking Stock News: Dive into DWTX Ticker-Specific Updates for Smart Investing
GlobeNewswire
2 days ago
Dogwood Therapeutics Announces Fourth Quarter and Full Year 2024 Financial Results
MT Newswires
15 days ago
Dogwood Therapeutics Begins Dosing in Mid-Stage Study of Halneuron for Chemotherapy-Related Neuropathic Pain
GlobeNewswire
15 days ago
Dogwood Therapeutics Announces Dosing of First Patient in Phase 2b Trial Evaluating Halneuron® in Patients with Chemotherapy-Induced Neuropathic Pain
Zacks Small Cap Research
16 days ago
DWTX: First Patient Dosed in Phase 2b Trial of Halneuron in CINP; Debt Conversion Strengthens Balance Sheet…
TipRanks
19 days ago
Biotech Alert: Searches spiking for these stocks today
MT Newswires
20 days ago
Sector Update: Health Care Stocks Softer Thursday Afternoon
MT Newswires
20 days ago
Dogwood Therapeutics Launches Registered Direct Offering; Shares Plunge
GlobeNewswire
20 days ago
Dogwood Therapeutics, Inc. Announces Pricing of $4.8 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules
Compare DWTX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "DWTX DOGWOOD THERAPEUTICS INC - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.